Pembrolizumab Inj Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 25 mg/mL
Reference Brands: Keytruda (USA/EU)
Category:
Oncology Cancer Care
Pembrolizumab is a humanized monoclonal antibody and an immune checkpoint inhibitor that targets the PD-1 (programmed death receptor-1) pathway. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), Pembrolizumab enhances T-cell mediated immune responses against cancer cells.
Pembrolizumab Inj is available in Injection
and strengths such as 25 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pembrolizumab Inj is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pembrolizumab Inj can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pembrolizumab is an immunotherapy medication used in the treatment of various advanced and metastatic cancers. It belongs to a class of drugs known as immune checkpoint inhibitors and works by enhancing the body’s immune response against cancer cells. Pembrolizumab specifically targets the programmed death-1 (PD-1) receptor on T-cells, helping restore the immune system’s ability to recognize and attack tumor cells more effectively.
This medication is widely used for the management of several oncologic conditions, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, and certain other solid tumors. By blocking the PD-1 pathway, pembrolizumab helps prevent cancer cells from evading immune detection, making it an important advancement in modern cancer immunotherapy.
Pembrolizumab is administered by intravenous infusion under the supervision of healthcare professionals and requires careful patient monitoring due to potential immune-related side effects. In addition to its approved indications, ongoing clinical research continues to explore its use in additional cancer types and treatment combinations. As a result, pembrolizumab has become a key therapeutic option in the evolving field of cancer treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing